EUVIMEDEUVIMED entdecken
Crossref

CD44-targeted melanin-based nanoplatform for alleviation of ischemia/reperfusion-induced acute kidney injury

Jinghua Sun, Xuhui Zhao, Hao Shen, Jie Dong, Shuo Rong, Wenwen Cai, Ruiping Zhang

Journal of Controlled Release · 2024

DOI: 10.1016/j.jconrel.2024.02.021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Jinghua Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: First Hospital of Shanxi Medical University, Taiyuan, 030001, China; Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Aca…. Hauptthemen laut MEDLINE: Acute Kidney Injury, Reperfusion Injury. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 51 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ischemia/reperfusion (I/R)-induced acute kidney injury (AKI) is a serious kidney disease with high morbidity and mortality. However, there is no effective clinical treatment strategy. Herein, we developed a CD44 targeting nanoplatform based on HA-assembled melanin NPs covalently coupled with dexamethasone for I/R-induced AKI therapy by alleviating oxidative/inflammatory- induced damage. The constructed HA-MNP-DXM NPs had good dispersion, stability, and broad-spectrum scavenging capabilities against multiple reactive free radicals. Moreover, the NPs could be efficiently internalized and exhibited antioxidative, anti-inflammatory, and antiapoptotic effects in CoCl2-stimulated renal tubular epithelial NRK-52E cells. Furthermore, the I/R-induced AKI murine model was established to evaluate the in vivo performance of NPs. The results suggested the NPs could specifically target impaired kidneys upon intravenous administration according to NIR-II fluorescence imaging and showed high biosafety. Importantly, the NPs could improve renal function, alleviate oxidative stress and inflammatory reactions, inhibit apoptosis of tubular cells, and restore mitochondrial structure and function, exhibiting excellent therapeutic effects. Further therapeutic mechanism indicated the NPs maintained the cellular/mitochondrial redox balance by modulating the Nrf2 and HO-1 expression. Therefore, the NPs can be a promising therapeutic candidate for the treatment of I/R-induced AKI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Kidney InjuryReperfusion InjuryMiceAnimalsMelaninsKidneyReperfusionIschemiaApoptosis

Stichwörter der Autor:innen

Acute kidney injuryDexamethasoneHyaluronic acidIschemia-reperfusionMelanin nanoparticles

Substanzen

Melanins

Autor:innen und Institutionen

  • First Hospital of Shanxi Medical University, Taiyuan, 030001, China; Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, Chi…
  • First Hospital of Shanxi Medical University, Taiyuan, 030001, China.
  • School of Pharmacy, Shanxi Medical University, Taiyuan, 030001, China.
  • Shanxi Medical University, Taiyuan, 030001, China.
  • Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, China.
  • The Radiology Department of Shanxi Provincial People' Hospital, Five Hospital of Shanxi Medical University, Taiyuan, 030001, China. Electronic address: zrp_7142@sxmu.edu.cn.

Zitieren

APA

Sun, J., Zhao, X., Shen, H., Dong, J., Rong, S., Cai, W., & Zhang, R. (2024). CD44-targeted melanin-based nanoplatform for alleviation of ischemia/reperfusion-induced acute kidney injury. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.02.021

Vancouver

Sun J, Zhao X, Shen H, Dong J, Rong S, Cai W, et al. CD44-targeted melanin-based nanoplatform for alleviation of ischemia/reperfusion-induced acute kidney injury. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.02.021

BibTeX
@article{Sun2024,
  author = {Sun, Jinghua and Zhao, Xuhui and Shen, Hao and Dong, Jie and Rong, Shuo and Cai, Wenwen and Zhang, Ruiping},
  title = {CD44-targeted melanin-based nanoplatform for alleviation of ischemia/reperfusion-induced acute kidney injury},
  journal = {Journal of Controlled Release},
  year = {2024},
  doi = {10.1016/j.jconrel.2024.02.021}
}
Kostenlos starten →